The National Pancreatic Cyst Registry is a prospective study of Integrated Molecular Pathology (IMP), which can predict the malignant potential of pancreatic cysts. Leading academic medical centers and community-based practices participated. The goals of the study were to evaluate the performance characteristics and clinical utility of IMP and determine the predictive value of both traditional first-line tests and integrated molecular pathology. This study evaluated the ability of PathFinderTG® (PancraGEN®) to accurately risk-stratify patients with pancreatic cysts according to their malignant potential. RedPath Integrated Pathology, Inc. (Interpace Diagnostics), provided sponsorship in part.